TFM
HOWL icon

TFC Financial Management’s Werewolf Therapeutics HOWL Stock Holding History

TFC Financial Management’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,500
Closed -$3.75K – 1061
2026
Q1 		$3.75K Hold
4,500
– – ﹤0.01% 485
2025
Q4 		$2.85K Buy
4,500
+2,000
+80% +$2.43K ﹤0.01% 497
2025
Q3 		$4.92K Hold
2,500
– – ﹤0.01% 461
2025
Q2 		$2.73K Hold
2,500
– – ﹤0.01% 476
2025
Q1 		$2.43K Hold
2,500
– – ﹤0.01% 473
2024
Q4 		$3.7K Buy
2,500
+1,000
+67% +$2.04K ﹤0.01% 445
2024
Q3 		$3.18K Hold
1,500
– – ﹤0.01% 458
2024
Q2 		$3.66K Buy
+1,500
New +$7.2K ﹤0.01% 420

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
VA
Verdad Advisers Boston, Massachusetts $104M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

TFC Financial Management's HOWL Position: Q2 2026 in Review

TFC Financial Management sold out of Werewolf Therapeutics (HOWL) in Q2 2026, closing a stake of 4,500 shares — an estimated $3.75K sold.

TFC Financial Management first reported a position in HOWL in Q2 2024 and held it in 8 quarters. The position peaked at $4.92K in Q3 2025. 45 funds tracked by Wall St. Rank hold HOWL as of Q2 2026.

  • TFC Financial Management reported no remaining Werewolf Therapeutics position as of Q2 2026 after selling out during the quarter.
  • TFC Financial Management sold 4,500 Werewolf Therapeutics shares in Q2 2026, an estimated $3.75K.
  • TFC Financial Management first reported a position in Werewolf Therapeutics in Q2 2024 and held it in 8 quarters.
  • TFC Financial Management's Werewolf Therapeutics position peaked at $4.92K in Q3 2025.
  • 45 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2026.

Based on TFC Financial Management's 13F filing for Q2 2026, filed 23 Jul 2026.